Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort-Reference-Cited by-同舟云学术

Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort

Published:2023-02-16 Issue:4 Volume:7 Page:525-528
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Reda Gianluigi¹^ORCID,Mattiello Veronica¹,Frustaci Anna Maria²^ORCID,Visentin Andrea³^ORCID,Mauro Francesca Romana⁴,Innocenti Idanna⁵,Gentile Massimo⁶,Giannarelli Diana⁷,Noto Alessandro¹,Cassin Ramona¹,Neri Antonino⁸,Laurenti Luca⁵^ORCID,Tedeschi Alessandra²

Affiliation:

1. 1Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

2. 2Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

3. 3Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy

4. 4Hematology, Department of Translational and Precision Medicine, ‘Sapienza’ University, Rome, Italy

5. 5Dipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Rome, Italy

6. 6Azienda Ospedaliera of Cosenza, Cosenza, Italy

7. 7Biostatistic Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

8. 8Scientific Directorate Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/4/525/2036061/blooda_adv-2022-007619-main.pdf

Reference25 articles.

1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL;Hallek;Blood,2018

2. Ibrutinib in CLL/SLL: from bench to bedside (review);Zi;Oncol Rep,2019

3. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

4. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study;Burger;Leukemia,2020

5. Ibrutinib for chronic lymphocytic leukemia with TP53 Alterations;Ahn;N Engl J Med,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort;Hematological Oncology;2024-01

2. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study;Frontiers in Oncology;2022-11-21